2.5 mg semaglutide Flex-Dose 2 mL Injectable mg/mL Semaglutide OL 12.5mg 2.5mg/ml x
Description
The graphs looks basically identical, with the rebound being quite sharp

Semaglutide for managing overweight and obesity Chapter 1: Recommendations (TA875)

Clinical Results of Tirzepatide On November 8, 2023, the FDA approved tirzepatide for long-term weight control

FDA engagement planned via an End-of-Phase 2 meeting in Q1 2026

J.MuthuchamyM

5 Appetite, satiety, and behavioral peptide systems revisited Regulation of appetite and feeding behavior represents one of the most extensively investigated yet paradoxically undertranslated domains of peptide biology
